News Sentiment

ABUS sentiment intelligence

Arbutus Biopharma Corp news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.56 Week of 17 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

76/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend active

-5.0% over one week, +0.2% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances

Market Reaction

Price moving ahead of tone

66/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 76/100 classification
One-week reaction -5.0% Price reacting lower
Trend fit Trend active 0.2% over four weeks
Fair value 32.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 21
Neutral 34
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
Stock Titan 9
GuruFocus 5
TradingKey 5
simplywall.st 4
Seeking Alpha 3
Investing.com 3
TradingView 3

Event Lens

What the news is about

Classified themes
Earnings 25
Market update 24
Regulatory and legal 4
Capital return 2
Balance sheet 1
Analyst action 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-58 of 58
Market source Direct company coverage

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

Arbutus Biopharma Corporation reported strong first-quarter 2026 financial results, including $179.1 million in total revenue, primarily from a litigation settlement with Moderna. The company also announced that its investigational drug, imdusiran, received Fast Track designation

Tone
Positive 75/100
Event
Earnings
Published
14 May 2026 00:40
Source
Market source
Investing.com Direct company coverage

Arbutus Biopharma earnings beat by $0.91, revenue topped estimates

Arbutus Biopharma (NASDAQ: ABUS) exceeded analyst expectations for its first-quarter earnings, reporting an EPS of $0.870 against an estimated $-0.040. The company's revenue also significantly topped estimates, coming in at $179.23M compared to the consensus of $400K. The stock h

Tone
Positive 90/100
Event
Earnings
Published
13 May 2026 12:39
Source
Investing.com
GuruFocus Direct company coverage

Arbutus Biopharma (ABUS) Reports Strong Q1 Earnings with $0.87 EPS

Arbutus Biopharma (ABUS) reported strong Q1 earnings with a GAAP EPS of $0.87 and revenue of $179.1 million, significantly boosted by a litigation settlement with Moderna. The FDA also granted fast track status to its lead asset, enhancing growth prospects. Despite a strong finan

Tone
Positive 76/100
Event
Earnings
Published
13 May 2026 12:39
Source
GuruFocus
Associated Press Direct company coverage

Arbutus: Q1 Earnings Snapshot

Tone
Neutral 50/100
Event
Earnings
Published
13 May 2026 11:36
Source
Associated Press
TradingView Direct company coverage

Arbutus Biopharma Corp 1Q 2026: Revenue $179.13M, EPS $0.87— 10-Q Summary

Arbutus Biopharma Corp reported a significant increase in first-quarter 2026 revenue to $179.13 million and diluted EPS of $0.87, driven primarily by a $178.7 million licensing settlement with Moderna. The company also highlighted pipeline progress for imdusiran, which received F

Tone
Positive 74/100
Event
Earnings
Published
13 May 2026 11:39
Source
TradingView
Stock Titan Direct company coverage

Moderna settlement drives Arbutus (NASDAQ: ABUS) to $169.7M Q1 profit

Arbutus Biopharma reported a significant Q1 2026 profit of $169.7 million, primarily driven by a $178.7 million license revenue from its share of Genevant's settlement with Moderna. This settlement, which includes a noncontingent payment and a potential contingent payment of up t

Tone
Positive 72/100
Event
Earnings
Published
13 May 2026 11:39
Source
Stock Titan
Stock Titan Direct company coverage

Arbutus (NASDAQ: ABUS) swings to Q1 profit on $179M revenue surge

Arbutus Biopharma (NASDAQ: ABUS) reported a significant turnaround in Q1 2026, swinging to a net income of $169.7 million on $179.1 million in revenue, primarily driven by a litigation settlement with Moderna. The company expects to receive $178.7 million from a $950 million upfr

Tone
Positive 91/100
Event
Earnings
Published
13 May 2026 11:39
Source
Stock Titan